Evolus, Inc. (EOLS) shares rallied 28.3% in the last trading session to close at $13.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3% loss over the past four weeks.

The sharp upsurge in EOLS shares can be attributed to positive market sentiment surrounding the company’s impressive preliminary results and strong growth outlook. Evolus reported a strong preliminary Q4 2024 performance, posting $79 million in sales, a 30% year-over-year increase, and surpassing expectations. Investors are optimistic about the company’s continued growth, as it projects net revenues of $345 million to $355 million in 2025, a 30% to 33% growth from 2024. Additionally, the company’s upcoming product launches, including FDA approvals for Evolysse Form and Evolysse Smooth, have further fueled investor confidence. With these promising developments, Evolus is positioned for continued earnings and revenue growth, driving the stock’s upward momentum.

This company is expected to post quarterly earnings of $0.04 per share in its upcoming report, which represents a year-over-year change of +128.6%. Revenues are expected to be $77.2 million, up 26.6% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Evolus, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on EOLS going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Evolus is a member of the Zacks Medical - Products industry. One other stock in the same industry, OrganiGram (OGI), finished the last trading session 0.7% lower at $1.54. OGI has returned -1.9% over the past month.

OrganiGram's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.03. Compared to the company's year-ago EPS, this represents a change of +78.6%. OrganiGram currently boasts a Zacks Rank of #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Evolus, Inc. (EOLS) : Free Stock Analysis Report

Organigram Holdings Inc. (OGI) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research